Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

GDC-6988

Phase 1Small molecule

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Non-Cystic Fibrosis BronchiectasisRecruiting

Non-Cystic Fibrosis BronchiectasisPhase 1

Recruiting

Timeline

Expected Milestones

Q4 2027

Phase 1Recruiting

Non-Cystic Fibrosis Bronchiectasis

NCT06603246

Clinical

Trials by Indication[1]

Non-cystic Fibrosis Bronchiectasis1 trial

A Phase Ic, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, and Activity of Inhaled GDC-6988 in Patients With Muco-obstructive Disease

Recruiting· Roche logo

Roche·Phase 1·NCT06603246·128 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for GDC-6988. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GDC-6988 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GDC-6988. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Roche

Related News